DUX4 and facioscapulohumeral muscular dystrophy: Having established proof-of-principle for using miR-675 as a potential therapy for FSHD, we next assessed the possibility of using small molecules to upregulate miR-675 as potential DUX4-targeting therapeutics, which was the main aim of our study.